Case analysis of acute eosinophilic pneumonia caused by recombinant human granulocyte stimulating factor (rhG-CSF)
10.12206/j.issn.1006-0111.202202029
- VernacularTitle:重组人粒细胞刺激因子致急性嗜酸性粒细胞肺炎的病例分析
- Author:
Runan QU
1
;
Jialong FAN
1
;
Hui LIU
1
;
He ZHANG
1
;
Junqin MAO
1
Author Information
1. Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 800 Huangjiahuayuan Rode, Shanghai 201803, P.R.China.
- Keywords:
recombinant human granulocyte stimulating factor;
drug-induced lung injury;
eosinophilic pneumonia;
adverse drug reaction
- From:
Journal of Pharmaceutical Practice
2022;40(4):364-367
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the role of clinical pharmacists in identifying adverse drug reactions (ADR), to draw clinical attention to the possibility of drug-induced lung injury caused by rhG-CSF, and distinguish them from infectious diseases. Methods A case of rhG-CSF induced acute lung injury was analyzed. After analyzing the relationship between rhG-CSF and acute eosinophilic pneumonia, exploring the possible mechanism, in combination with the patient's condition, the clinical pharmacist put forward the suggestion for the treatment of the disease. Results After receiving rhG-CSF, the patient's eosinophils increased, the pneumonia was aggravated, and the effect of anti-infection treatment was poor. Eosinophils pneumonia associated with rhG-CSF was considered. The patient's pulmonary symptoms improved after treatment with glucocorticoid in combination with withdrawal of antibiotics and antiviral drugs, and eosinophil returned to normal. Conclusion rhG- can cause rare eosinophilic pneumonia. The clinical pharmacist's participation in clinical treatment can help to identify drug-induced diseases, reorient the direction of treatment and ensure the success of clinical therapy.
